The repeated failures of amyloid-targeting therapies have challenged our narrow
understanding of Alzheimer's disease (AD) pathogenesis and inspired wide-ranging …

Clinical trials of novel therapeutics for Alzheimer's Disease (AD) have consumed a large
amount of time and resources with largely negative results. Repurposing drugs already …

Alzheimer's disease (AD), the most common form of dementia, is recognized as a
heterogeneous disease with diverse pathophysiologic mechanisms. In this study, we …

To identify the molecular mechanisms and novel therapeutic targets of late-onset
Alzheimer's Disease (LOAD), we performed an integrative network analysis of multi-omics …

Glial cells, including astrocytes, oligodendrocytes, and microglia, are the major components
in the central nervous system (CNS). Studies have revealed the heterogeneity of each glial …

The innate immune response influences neural repair after spinal cord injury (SCI). Here, we
combined myeloid-specific transcriptomics and single-cell RNA sequencing to uncover not …

Background Mouse models have allowed for the direct interrogation of genetic effects on
molecular, physiological, and behavioral brain phenotypes. However, it is unknown to what …

In molecular biology and genetics, there is a large gap between the ease of data collection
and our ability to extract knowledge from these data. Contributing to this gap is the fact that …

In recent decades, our understanding of the molecular changes involved in
neurodegenerative diseases has been transformed. Single-cell RNA sequencing and single …

Alzheimer's disease (AD) is a neurodegenerative disorder causing 70% of dementia cases.
However, the mechanism of disease development is still elusive. Despite the availability of a …